GRCE (Grace Therapeutics) Total Operating Expense: $11.08 Mil (TTM As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.35
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Total Operating Expense?

Grace Therapeutics GRCE +1.06% 31 Total Operating Expense is $11.08 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $3.01 Mil. Grace Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $11.08 Mil.

Grace Therapeutics Total Operating Expense Related Terms

Grace Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Total Operating Expense Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.34 18.25 11.37 16.68 11.08

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.18 3.09 2.53 2.45 3.01
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $11.08 Mil mean?
Grace Therapeutics (GRCE) has a Total Operating Expense of $11.08 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' Total Operating Expense too high?
Grace Therapeutics' current Total Operating Expense is $11.08 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Total Operating Expense compare to INMB and ABVC?
Grace Therapeutics' Total Operating Expense of $11.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Total Operating Expense is $11.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Total Operating Expense of $11.08 Mil. The current Total Operating Expense is $11.08 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Total Operating Expense is $11.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35
Price